More about screening … current and future issues

So there are two new articles recently published on the prostate cancer screening issue. One deals with the numbers of men  in America who seem to be getting screened today. The other addresses whether there should be different guidance on prostate cancer screening for African Americans as opposed to “the rest of us” (Caucasians, Hispanics, and “white” Americans). … READ MORE …

Enter the “director of prostate imaging” (at least at some centers)

As regular readers are well aware, there has for a while been an increase in the importance of new forms of high quality imaging studies in the diagnosis, work-up, and monitoring of men with prostate cancer (localized, locally advanced, and advanced). … READ MORE …

Aggressive, trimodal therapy active in treatment of selected men with M1 prostate cancer

A new report in the journal Urology has shown that a subset of men with metastatic disease can be placed in long-term remission through the use of a combination of androgen deprivation therapy (ADT) + surgery + radiation therapy. … READ MORE …

AUA, others comment on new USPSTF draft on screening for risk of prostate cancer

The American Urological Association (AUA), along with other organizations, issued a statement yesterday regarding their reactions to the new, draft guidance issues by the U.S. Preventive Services Task Force (USPSTF). … READ MORE …

How primary care physicians could better help prostate cancer patients

A newly published article on the Journal of the American Board of Family Medicine offers some helpful guidance to primary care  physicians on the subject of prostate cancer diagnosis and its management. … READ MORE …

State of the art lectures at the EAU meeting in London

Recently posted on the UroToday web site are summaries of four “state-of-the-art” lectures on prostate cancer and its management presented a couple of weeks ago at the annual meeting of the European Association of Urology is London. … READ MORE …

Genomic prediction of risk for biochemical relapse post-surgery

Yet another genetic/genomic test (this one developed by Metamark Genetics) may have value in the assessment of risk for biochemical progression after first-line surgery for prostate cancer. … READ MORE …